Boehringer Ingelheim
Darko Stevanovic, MD, PhD, is currently a Senior Director and Clinical Development Lead for Cardio-Renal-Metabolic Diseases at Boehringer Ingelheim, overseeing clinical development plans and trial designs since December 2024. With a robust background in clinical development gleaned from previous roles at Sarepta Therapeutics, Nova Biomedical, and Teva Pharmaceuticals, Stevanovic has extensive experience in medical strategy, cross-functional collaboration, and regulatory affairs. Stevanovic holds a Doctor of Philosophy in Medicine and a Doctor of Medicine degree from the University of Belgrade, along with additional training in translational medicine and leadership from Harvard University. Throughout an academic career that included positions as Research Fellow and Assistant Professor, Stevanovic has contributed significantly to the fields of endocrinology and medical physiology.
This person is not in any teams
This person is not in any offices
Boehringer Ingelheim
116 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.